The Society for Immunotherapy of Cancer (SITC) published it's first clinical practice guideline (CPG) for the use of immunotherapy for the treatment of Bladder Carcinoma in the Journal for ImmunoTherapy of Cancer in 2017. An update to this guideline is currently in progress and anticipated to publish in early 2021.SITC's Cancer Immunotherapy Guidelines program is a collection of CPGs developed by multi-disciplinary panels of experts who draw from their own practical experience as well as evidence in the published literature and clinical trial data to develop evidence- and consensus-based recommendations. SITC uses as a model the Institute of Medicine's 2011 "Standards for Developing Trustworthy Clinical Practice Guidelines" to ensure the recommendations are unbiased, transparent and balanced.The 2017 guideline covers the immunotherapeutic drugs approved for the treatment of bladder cancer include several checkpoint inhibitors and the immunotherapeutic vaccine, Bacillus Calmette-Guérin (BCG).This guideline will aid oncologists in effective clinical decision-making concerning patient selection, toxicity management, response evaluation, and the sequencing or combination of therapies, and patient quality of life issues.
The Society for Immunotherapy of Cancer (SITC) Urothelial Cancer Immunotherapy Guideline Expert Panel is pleased to invite public comment from February 11 – March 1, 2021 for the draft of the forthcoming, “Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of urothelial cancer” manuscript.
SITC’s public open comment period allows for key stakeholders and other experts in the field – both within and outside of our membership – to provide comment on the confidential manuscript draft prior to publication. SITC is committed to maintaining full transparency in our guideline development process, in alignment with the Institute of Medicine’s standards, for the ultimate purpose of developing quality clinical practice guidelines to aid practitioners in providing the best possible care to their patients.
All comments received during the open comment period will be reviewed by the Urothelial Cancer Immunotherapy Guideline Expert Panel leadership. Comments are advisory only and SITC is not obligated to make any suggested changes based on comments received. SITC will consider all submissions, but will not respond directly to individual commenters.
Published Aug. 15, 2017 in the Journal for ImmunoTherapy of Cancer (JITC) as "The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of bladder carcinoma."
Arjun V. Balar, MD — Perlmutter Cancer Center - New York University Langone Medical Center
Peter Black, MD, FACS, FRCSC — The University of British Columbia
Matthew T. Campbell, MD, MS — The University of Texas MD Anderson Cancer Center
Gail S. Dykstra, Patient Research Advocate — Bladder Cancer Advocacy Network (BCAN); Dykstra Research
Petros Grivas, MD, PhD — University of Washington
Shilpa Gupta, MD — Cleveland Clinic Taussig Cancer Institute
Christopher J. Hoimes, MD — Duke Cancer Institute
Lidia P. Lopez, APN-C — The University of California Los Angeles
Joshua J. Meeks, MD, PhD — Northwestern Medicine Feinberg School of Medicine
Elizabeth R. Plimack, MD, MS — Fox Chase Cancer Center
Jonathan E. Rosenberg, MD — Memorial Sloan Kettering Cancer Center
Neil Shore, MD, FACS — Carolina Urologic Research Center
Gary D. Steinberg, MD — Perlmutter Cancer Center - New York University Langonge Medical Center
Tel: +1 414 271 2456 | Fax: +1 414 276 3349 | Email: firstname.lastname@example.org